Therapeutic window assays for NK-engagers: Killing activity tumor cells vs progenitors

Ex vivo estimation of Daratumumab Hematotoxicity in Killing Progenitors results in a Therapeutic Window assay

  • Daratumumab is less active on Healthy CD34+CD38- progenitor cells.

Figure 1. Dose response curves of daratumumab in plasmatic and progenitor cells

  • Specificity & Therapeutic Window ex vivo is higher at High CD38 Expression

Figure 2. Correlation between CD38 expression on different cellular subsets and activity (AUC) in MM patients